🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 13 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 13/01/2015 | 120,40 | 123,85 | 119,70 | 120,60 | +1,94% | 3,45% | 1.628.100 |
| 12/01/2015 | 123,01 | 124,40 | 117,73 | 118,31 | -3,19% | 5,42% | 2.783.200 |
| 09/01/2015 | 123,75 | 125,29 | 122,00 | 122,21 | -1,42% | 2,66% | 1.069.500 |
| 08/01/2015 | 122,00 | 124,00 | 121,14 | 123,97 | +2,74% | 2,34% | 1.358.300 |
| 07/01/2015 | 118,82 | 120,77 | 117,63 | 120,66 | +2,81% | 2,64% | 1.219.900 |
| 06/01/2015 | 121,31 | 122,58 | 116,80 | 117,36 | -3,03% | 4,76% | 2.289.700 |
| 05/01/2015 | 122,27 | 122,78 | 119,34 | 121,03 | -1,66% | 2,81% | 1.681.100 |
| 02/01/2015 | 119,97 | 123,68 | 118,30 | 123,07 | +3,59% | 4,48% | 1.434.500 |
| 31/12/2014 | 119,61 | 121,96 | 118,50 | 118,80 | -0,29% | 2,89% | 946.300 |
| 30/12/2014 | 119,36 | 120,42 | 119,01 | 119,15 | -0,53% | 1,18% | 861.200 |
| 29/12/2014 | 117,91 | 120,00 | 116,84 | 119,79 | +1,17% | 2,68% | 929.200 |
| 26/12/2014 | 115,56 | 118,83 | 115,51 | 118,41 | +2,83% | 2,87% | 573.300 |
| 24/12/2014 | 113,75 | 117,29 | 113,31 | 115,15 | +1,23% | 3,50% | 519.000 |
| 23/12/2014 | 117,53 | 119,54 | 109,34 | 113,75 | -2,51% | 8,68% | 4.062.300 |
| 22/12/2014 | 118,92 | 122,17 | 116,00 | 116,68 | -1,87% | 5,19% | 2.098.100 |
| 19/12/2014 | 117,25 | 124,35 | 116,76 | 118,90 | +0,99% | 6,47% | 6.131.400 |
| 18/12/2014 | 114,08 | 118,67 | 111,66 | 117,74 | +5,27% | 6,14% | 2.148.300 |
| 17/12/2014 | 110,37 | 112,95 | 108,70 | 111,85 | +0,89% | 3,85% | 2.554.200 |
| 16/12/2014 | 112,64 | 113,44 | 110,07 | 110,86 | -1,79% | 2,99% | 2.109.100 |
| 15/12/2014 | 120,17 | 120,24 | 112,59 | 112,88 | -4,78% | 6,37% | 2.138.000 |
| 12/12/2014 | 118,87 | 121,09 | 118,38 | 118,55 | -1,85% | 2,28% | 1.326.000 |
| 11/12/2014 | 118,12 | 122,26 | 117,20 | 120,78 | +3,05% | 4,28% | 1.299.800 |
| 10/12/2014 | 120,18 | 121,65 | 116,73 | 117,20 | -2,58% | 4,09% | 1.559.700 |
| 09/12/2014 | 118,33 | 120,80 | 116,79 | 120,30 | +0,77% | 3,39% | 1.056.700 |
| 08/12/2014 | 118,23 | 121,10 | 117,95 | 119,38 | +1,21% | 2,66% | 1.486.000 |
| 05/12/2014 | 118,49 | 118,84 | 117,05 | 117,95 | -0,64% | 1,51% | 1.123.100 |
| 04/12/2014 | 119,68 | 121,19 | 117,52 | 118,71 | -1,22% | 3,07% | 971.700 |
| 03/12/2014 | 120,20 | 121,88 | 119,00 | 120,18 | +1,03% | 2,40% | 1.083.600 |
| 02/12/2014 | 116,45 | 119,40 | 116,16 | 118,95 | +1,80% | 2,78% | 1.168.100 |
| 01/12/2014 | 117,89 | 119,76 | 115,37 | 116,85 | -0,87% | 3,72% | 1.101.000 |